Cambrian Bio to Showcase ATX-304 Research at ADA 2026
Cambrian Bio to Present Two Posters on ATX-304 at the American Diabetes Association 86th Scientific Sessions
Businesswire
Image: Businesswire
Cambrian Bio will present two posters on ATX-304 at the American Diabetes Association's 86th Scientific Sessions in New Orleans from June 5-8, 2026. The data will focus on a Phase 1b study of ATX-304 in obese and prediabetic participants and its mechanism of action.
- 01Cambrian Bio is presenting at the ADA 86th Scientific Sessions in New Orleans from June 5-8, 2026.
- 02The posters will detail findings from a Phase 1b clinical study of ATX-304, targeting obesity and prediabetes.
- 03ATX-304 is a first-in-class oral small molecule that activates AMPK and mitochondrial functions.
- 04CEO James Peyer emphasized the potential of ATX-304 to significantly impact metabolic health for millions.
- 05The abstracts will be available on June 5, 2026, and the posters will be accessible on Cambrian Bio's website after the presentation.
Advertisement
In-Article Ad
Cambrian Bio, a clinical-stage drug development firm, will present two posters on its lead therapeutic, ATX-304, at the American Diabetes Association's 86th Scientific Sessions from June 5-8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The presentations will include findings from a Phase 1b clinical study involving participants with obesity and prediabetes, as well as insights into the drug's mechanism of action. ATX-304 is a novel oral small molecule that acts as a combined adenosine monophosphate-activated protein kinase (AMPK) and mitochondrial activator, aimed at addressing obesity and other cardiometabolic diseases. CEO James Peyer expressed pride in the team's efforts and highlighted the drug's potential to transform the lives of those facing metabolic decline. The abstracts will be publicly accessible starting June 5, and the posters will be available on Cambrian Bio's website after the event.
Advertisement
In-Article Ad
The research could provide new insights into treatments for obesity and metabolic diseases, potentially benefiting local health outcomes.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of ATX-304 for treating obesity?
Connecting to poll...
Read the original article
Visit the source for the complete story.